Skip to main content
Clinical Trials/NCT05990673
NCT05990673Not yet recruitingNot Applicable

Determination of the 50% and 95% Effective Dose of Remimazolam for Intravenous Anesthesia Induction in Pediatric Patients

Zhihong LU0 sites25 target enrollmentStarted: August 10, 2023Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
25
Primary Endpoint
half effective dosage

Study Overview

Brief Summary

Remimazolam has demonstrated the potential as a valuable medication for procedural sedation and general anesthesia. However, the effective dosage of remimazolam in pediatric patients is still unknown.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
3 Years to 12 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • age from 3 to 12 years old
  • patients scheduled for surgery under general anesthesia

Exclusion Criteria

  • American Society of Anesthesiologists status >=Ⅲ
  • Body mass index>=28kg/m2
  • patients who cannot cooperate with intravenous anesthesia induction
  • patients with risk of difficult airway
  • patients who are allergic to benzodiazepines
  • patients with delayed neurologic function

Arms & Interventions

remimazolam

Experimental

remimazolam is given for anesthesia induction

Intervention: Remimazolam (Drug)

Outcomes

Primary Outcomes

half effective dosage

Time Frame: from injection of remimazolam to loss of consciousness, at an average of 5 minutes

the dosage by which half of the patients will be sedated

Secondary Outcomes

  • 95% effective dosage(from injection of remimazolam to loss of consciousness, at an average of 5 minutes)

Investigators

Sponsor
Zhihong LU
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Zhihong LU

Associate professor

Air Force Military Medical University, China

Similar Trials

Dose of Remi in Children | Clinical Trial